Skip to content

Evaluation of the clinical efficacy and mechanism of UVA1 in the treatment of alopecia areata

Evaluation of the clinical efficacy and mechanism of UVA1 in the treatment of alopecia areata

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100041844
Enrollment
Unknown
Registered
2021-01-07
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia areata

Interventions

experimental group 1:UVA1 60j /cm2+Compound Glycyrrhizin Tablets
experimental group 2:UVA1 100j /cm2+Compound Glycyrrhizin Tablets
Control group:Compound Glycyrrhizin Tablets

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The outpatient diagnosis of alopecia areata patients older than 12 years old is diagnosed in our clinic, and the SALT score of the severe hair loss tool is S1-S3. According to the diagnostic criteria, according to the third edition of Zhao Fen's "Clinical Dermatology": one or several round, oval or irregular hair loss areas suddenly appeared, and the local scalp was normal and smooth, without scales and inflammation.

Exclusion criteria

Exclusion criteria: 1. If you have not received other treatments within one month, if you have received hormones, immunosuppressive agents, etc. within one month, you can also be included after a 4-week washout period. 2. No underlying diseases such as lupus erythematosus, cataracts, xeroderma pigmentosum, skin tumors, photosensitivity diseases, etc. 3. No infectious disease within 1 month. 4. Have not used photosensitive drugs.

Design outcomes

Primary

MeasureTime frame
Cytokines;Histopathology;

Countries

China

Contacts

Public ContactSijian Wen

The First Affiliated Hospital of Guangxi Medical University

599062703@qq.com+86 13978150906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026